-4%

Semaglutide | Advanced GLP-1 Receptor Agonist Research Data

Name: Semaglutide | Advanced GLP-1 Receptor Agonist Research Data - TITANFORGE LABS
Price: 288.00 USD
Availability: InStock

Original price was: $300.00.Current price is: $288.00.

Semaglutide is a potent, synthetic GLP-1 receptor agonist designed for high metabolic stability and extended biological activity. As a 31-amino acid peptide, it acts as a long-acting analog of the incretin hormone glucagon-like peptide-1 (GLP-1). In advanced research settings, Semaglutide is investigated for its profound ability to stimulate glucose-dependent insulin secretion, suppress postprandial glucagon, and regulate appetite through central nervous system signaling.

Categories: GLP-1 & METABOLIC RESEARCH COMPOUNDS, RESEARCH-GRADE COMPOUNDS Tags: Diabetes Research, GLP-1, Incretin Mimetic, Metabolic Health, Obesity Research, Research Grade., Semaglutide

Description
Reviews (0)

Semaglutide: The Science of Sustained Incretin Agonism

The Biochemistry of Semaglutide

The structure of Semaglutide ( $C_{187}H_{291}N_{45}O_{59}$ ) is engineered for maximum durability against enzymatic degradation. The modification includes the substitution of Alanine with alpha-aminoisobutyric acid (Aib) at position 8 to resist dipeptidyl peptidase-IV (DPP-IV). Additionally, the attachment of a C-18 fatty diacid chain via a spacer at Lysine 26 facilitates high-affinity albumin binding, extending its half-life to approximately 165 hours in research models.

Mechanism of Action: GLP-1R Activation and Metabolic Control

In advanced endocrinology and metabolism research, Semaglutide functions through several coordinated physiological pathways:

Enhanced Insulinotropic Response: The peptide binds to the GLP-1 receptor on pancreatic beta cells, amplifying insulin secretion in a glucose-dependent manner.
Hepatic Glucose Modulation: Research focuses on the peptide’s capacity to inhibit glucagon release from alpha cells, effectively lowering hepatic glucose production.
Gastric Motility Regulation: Semaglutide is investigated for its role in slowing gastric emptying, which contributes to a more gradual absorption of nutrients.
Hypothalamic Signaling: The peptide penetrates specific brain regions to influence satiety and reward pathways, making it a focal point for studies involving energy intake and obesity.

Primary Research Applications

Chronic Weight Management Research: Investigating the impact of sustained GLP-1R signaling on body composition and total energy expenditure.
Metabolic Syndrome & T2D Modeling: Analyzing the restoration of glycemic stability and beta-cell responsiveness in dysfunctional metabolic states.
Cardiovascular Integrity Studies: Observing the peptide’s impact on markers of atherosclerosis, systemic inflammation, and endothelial health.
Neuroprotective Research: Studying the potential of GLP-1 analogs to mitigate neuro-inflammatory processes and preserve cognitive function.

4. Technical Specifications (E-E-A-T Data)

Feature	Scientific Specification
Peptide Type	GLP-1 Receptor Agonist (Incretin Mimetic)
Amino Acid Count	31 Amino Acids
Molecular Formula	$C_{187}H_{291}N_{45}O_{59}$
Molecular Weight	4113.58 g/mol
CAS Number	910463-68-2
Purity Grade	$\geq$ 99% (HPLC & Mass Spec Verified)
Modification	Aib substitution (Pos 8) & C-18 fatty diacid acylation
Solubility	Soluble in Water and Saline

5. Product FAQ

Q: How does Semaglutide differ from Liraglutide in research?

A: While both are GLP-1 agonists, Semaglutide features a C-18 fatty diacid and specific amino acid substitutions that provide a significantly longer half-life (~7 days) compared to Liraglutide (~13 hours). This allows for different observation intervals in research protocols.

Q: Why is the albumin binding significant for Semaglutide?

A: The acylation allows Semaglutide to bind reversibly to albumin. This protection prevents rapid renal filtration and protects the peptide from enzymatic cleavage, ensuring a sustained concentration of the research compound in the subject.